Tests MZE829 in adults with APOL1-related protein-leaking kidney disease
Tests the drug MZE829 in adults with kidney disease linked to the APOL1 gene.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Key facts
- Where
- Créteil, Lille, Lyon, Paris, and Saint-Ouen, FranceSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 68 years old?
Source: NCT06830629, who can take part
Where in France
- CréteilCréteil, FranceTaking people
- LilleLille, FranceTaking people
- LyonLyon, FranceTaking people
- ParisParis, FranceTaking people
- Saint-OuenSaint-Ouen, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maze Therapeutics
- Trial code
- NCT06830629
- Record updated
- 27 July 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.Read full original descriptionShow less
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
Inclusion: APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2; Chronic kidney disease with persistent albuminuria.
Exclusion: Organ or bone marrow transplantation; History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer; Conditions that may alter drug absorption, e.g., history of bariatric surgery; Type I diabetes; Pregnant or currently nursing; Other inclusion/exclusion criteria defined in protocol apply.